Biologics Contract Development Global Market Report 2022: Expanding Adoption of Cutting-Edge Technologies for Biological Production Drives 10% Annual Growth – ResearchAndMarkets.com

Biologics Contract Development Global Market Report 2022: Expanding Adoption of Cutting-Edge Technologies for Biological Production Drives 10% Annual Growth – ResearchAndMarkets.com




Biologics Contract Development Global Market Report 2022: Expanding Adoption of Cutting-Edge Technologies for Biological Production Drives 10% Annual Growth – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Biologics Contract Development Market by Product Service, by Indication, by Source, and by Region – Global Forecast to 2022-2033” report has been added to ResearchAndMarkets.com’s offering.

The biologics contract development market size is estimated to be USD 5,672.1 million in 2022 and is expected to witness a CAGR of 10.71% during the forecast period 2023-2033. Rising M&A activity, expanding adoption of cutting-edge technologies for biological production, increase in the outsourcing of R&D by pharmaceutical and biopharma companies, and a supportive regulatory environment for clinical trials in developing countries are factors contributing to the market growth.

Furthermore, an increase in the incidence of disorders such neurological disorders, gynaecological disorders, cancer, ophthalmic disorders, and cardiovascular problems and rising collaboration of CROs for research is predicted to support the market growth. However, lack of knowledge regarding the usage of products and high price of production is expected to hinder the growth.

Increase in the incidence of disorders such neurological disorders, gynaecological disorders, cancer, ophthalmic disorders, and cardiovascular problems is projected to spur the market.

For instance, the WHO reports that one of the major causes of death worldwide and the cause of more than 10 million deaths in 2020 was cancer. According to Cancer Tomorrow, additional cancer cases are anticipated in the years to come. Over 19.3 million incidences of cancer were reported in 2020, and based on estimates from Cancer Tomorrow, this number is projected to increase to 30.2 million by 2040. In these circumstances, healthcare CDMOs are essential to the patient’s care since many biopharma companies aim to create advance treatments.

Rising collaboration of CROs for research is expected to fuel the market growth. Furthermore, CROs are forming alliances for the study of other diseases like cancer, Alzheimer’s, and other diseases in the post-pandemic era. For instance, in April 2022, Labcorp and Xcell Biosciences collaborated to help the other’s initiatives to develop cell and gene therapies for the treatment of Parkinson’s, cancer, and other uncommon diseases. In the post-pandemic era, this should enhance study on these diseases.

Segmentation

By Product Service

The market is categorized into process development, cell line development, and others. In 2022, the process development segment accounted for the highest revenue share due to the fact that many companies are preferring to outsource the manufacturing of recombinant proteins and monoclonal antibodies.

By Indication

The market is categorized into cardiovascular disorder, oncology, haematological disorders, immunological disorders, and others. In the global market, the oncology segment accounted for the largest revenue share in 2022 owing to increasing investment in novel cancer treatments by various pharmaceutical and biopharmaceutical companies.

By Source

The market is divided into mammalian, microbial, and others. In 2022, the mammalian segment accounted for the largest revenue share owing to the major advantage of manufacturing mammalian proteins with appropriate post-translational modifications that provide a native structure when using mammalian cells for protein expression.

Segmentation: Biologics Contract Development Market Report 2022 – 2033

Product Service (Revenue, USD Million), 2022 – 2033

Process Development

  • Downstream
  • Upstream
  • By Product
  • Others

Cell Line Development

  • Mammalian
  • Microbial
  • Others
  • Others

Indication (Revenue, USD Million), 2022 – 2033

  • Cardiovascular Disorder
  • Oncology
  • Haematological Disorders
  • Immunological Disorders
  • Others

Source (Revenue, USD Million), 2022 – 2033

  • Mammalian
  • Microbial
  • Others

By Region (Revenue, USD Million), 2022 – 2033

North America

  • U.S
  • Canada

Europe

  • Germany
  • France
  • UK
  • Spain
  • Italy
  • Rest of Europe

Asia Pacific

  • China
  • Japan
  • India
  • Australia
  • South Korea
  • Rest of APAC

Latin America

  • Brazil
  • Mexico
  • Argentina
  • Rest of LATAM

Middle East & Africa

  • South Africa
  • GCC
  • Rest of MEA

Companies Mentioned

  • Abzena Ltd
  • Fujifilm Diosynth Biotechnologies
  • AGC Biologics
  • Thermo Fisher Scientific Inc.
  • Bionova Scientific Inc.
  • WuXi Biologics
  • Curia Global Inc.
  • Genscript
  • KBI Biopharma
  • BioXcellence (Boehringer Ingelheim Biopharmaceuticals GmbH)
  • STC Biologics.

For more information about this report visit https://www.researchandmarkets.com/r/36qs5

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./ CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900